Journal article
Phase II trial of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of anaplastic astrocytoma
Journal of radiation oncology, v 2(1)
01 Mar 2013
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective The efficacy and safety of adjuvant radioimmunotherapy with I-125-labeled anti-epidermal growth factor receptor 425 murine antibody (I-125-425 mAb) in patients with newly diagnosed anaplastic astrocytoma (AA) is evaluated in this single-institution phase II study.
Methods Patients with newly diagnosed and histologically proven AA were eligible. A total of 80 patients received three weekly intravenous injections of 1.8 GBq of I-125-425 mAb following surgery and radiation therapy to a median dose of 60 Gy. Median overall survival was the primary endpoint and the secondary endpoint was toxicity.
Results The median age was 43 years (range 22-75 years), and the median Karnofsky Performance Status was 80 (range 50-100). The percentage of patients who under-went surgical debulking, radiation therapy, temozolomide, and nitrosourea-based chemotherapy are 57.5, 99, 25, and 25 % respectively. The overall median survival was 55.6 months (95 % CI 42.7-68.5 months). The 2-and 5-year survivals were 74 and 47 %, respectively. There was no grade 3 or higher toxicity with the administration of I-125-425 mAb.
Conclusion Treatment with I-125-425 mAb in newly diagnosed AA patients was safe and well tolerated. Survival benefits are encouraging and warrant further study.
Metrics
5 Record Views
Details
- Title
- Phase II trial of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of anaplastic astrocytoma
- Creators
- Ji H. Kim - City Of Hope National Medical CenterLinna Li - Bryn Mawr HospitalTony S. Quang - VA Puget Sound Health Care SystemJacqueline G. Emrich - Drexel UniversityTheodore E. Yaeger - Wake Forest UniversityJoseph M. Jenrette - Medical University of South CarolinaSteven C. Cohen - Bryn Mawr HospitalPerry Black - Drexel UniversityLuther W. Brady - Drexel University
- Publication Details
- Journal of radiation oncology, v 2(1)
- Publisher
- Springer Nature
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine); [Retired Faculty]
- Web of Science ID
- WOS:000218723900002
- Other Identifier
- 991019168624504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology